ISG15 Antikörper (N-Term)

Produktnummer ABIN356679

Produktdetails anti-ISG15 Antikörper

Target: ISG15 (ISG15 Ubiquitin-Like Modifier (ISG15))

Bindungsspezifität: AA 39-68, N-Term

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ISG15 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Spezifität: This antibody is specific to ISG15 (N-term).

Aufreinigung: Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Immunogen: KLH conjugated synthetic peptide between 39~68 amino acids from the N-terminal region of Human ISG15. Genename: ISG15

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000. Western blot: 1/100-1/500. Immunohistochemistry: 1/50-1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Details zu ISG15

Target: ISG15 (ISG15 Ubiquitin-Like Modifier (ISG15))

Andere Bezeichnung: ISG15 / G1P2 (ISG15 Produkte)

Synonyme: G1P2 antikoerper, IFI15 antikoerper, IP17 antikoerper, UCRP antikoerper, hUCRP antikoerper, ISG15 antikoerper, g1p2 antikoerper, si:rp71-1c23.2 antikoerper, G1p2 antikoerper, IGI15 antikoerper, Irfp antikoerper, ISG17 antikoerper, ISG17/UCRP antikoerper, ISG15 ubiquitin-like modifier antikoerper, ISG15 antikoerper, isg15 antikoerper, Isg15 antikoerper

Hintergrund: ISG15 is secreted from monocytes in response to type I interferons and causes natural killer (NK)-cell proliferation and an augmentation of non-MCH (major histocompatibility complex)-restricted cytotoxicity. Synthesis is stimulated by IFN-alpha or IFN-beta or IFN-omega , but not IFN-gamma . ISG15 expression is also induced by overexpression of interferon regulatory factors that participate in transcriptional regulation of IFN genes, and by influenza B virus. ISG15 is secreted also by cell lines of monocyte, T-lymphocyte, B-lymphocyte, human fibroblasts, and epithelial origins. The induction of terminal differentiation in human melanoma cells is associated with alterations in ISG15 expression. Enhancement of NK cell proliferation, augmentation of non-major histocompatibility complex-restricted cytotoxicity, and induction of IFN-gamma from T cells identify ISG15 as a member of the cytokine cascade and suggest that it may be responsible for amplifying and directing some of the immunomodulatory effects of IFN-alpha or IFN-beta. ISG15 has has also been shown to function intracellularly as a ubiquitin homolog.Synonyms: Interferon-induced 15 kDa protein, Interferon-induced 17 kDa protein, UCRP, Ubiquitin cross-reactive protein

Gen-ID: 9636, 9606

UniProt: P05161